FABASOFT
29.3.2021 15:35:10 CEST | Business Wire | Press release
Fabasoft, a leading European provider of cloud solutions, was invited by Forrester to take part in an independent overview of “Content Platforms” (“The latest stage of evolution in the market traditionally known as Enterprise Content Management Systems”).
Research and advisory firm Forrester Research Inc. overviewed 38 top cloud content platforms based on platform capabilities, vertical focus, and size.
One of the key takeaways according to the authors of the “Now Tech: Content Platforms, Q1 2021” analysis* indicates that “…small and midsize vendors may offer a better range of content services and expertise in specific vertical markets.” Yet the study’s authors also offer the following words of caution: “Be wary of ‘cloudwashing’ when older technologies are hosted but branded as cloud.”
The functionality of Fabasoft Business Process Cloud as a multi-client cloud content platform covers categories addressed in the study such as “Collaborative Content Services” and “Transactional Content Services and Multitenant Cloud Content Platforms.”
Download now: Now Tech: Content Platforms, Q1 2021
“We believe being listed in the report as a native cloud provider with three of the four primary functionality segments attests to the capabilities and performance of the Fabasoft Business Process Cloud,” remarks a delighted Andreas Dangl, Business Unit Executive Cloud and digitalization expert at Fabasoft.
“With its process-driven cloud platform, Fabasoft specializes in document-centric business workflows for manufacturing, financial services, as well as architecture, engineering, and construction. Among our strengths is efficient ‘low-code’ or ‘no-code’ customizing – in other words, tailoring our products to customer requirements without the need for elaborate programming. The broad range of standard interfaces also makes it easier to connect to existing IT systems,” explains Dangl.
Forrester Now Tech is an independent and objective overview of providers focusing on a specific IT solution area.
Download now: Now Tech: Content Platforms, Q1 2021
*Forrester Now Tech: Content Platforms, Q1 2021, Cheryl McKinnon with Daniel Hong, Hailey Colin, and Sam Bartlett.
Using the Fabasoft Business Process Cloud , companies can shape their business processes and work with digital content across organizations, IT infrastructures, and countries. Fabasoft Business Process Cloud’s out-of-the-box solutions and scalable applications empower organizations to bring the focus back to their customers as they move their digital transformation forward. Companies in the industrial sector appreciate the platform’s advantages, particularly when it comes to handling major projects and implementing processes in documentation and product management. Functionalities such as workflow automation and modeling, well-defined authorization and role models, transparent versioning, automatic synchronization, and mobile use facilitate collaboration and ensure seamless transparency.
About Fabasoft
Fabasoft is among the leading software product companies and cloud service providers in Europe for digital document management as well as electronic document, process, and records management. For more than three decades, numerous prominent private enterprises and public sector organizations have placed their trust in Fabasoft’s long-standing quality and experience.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005489/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom